LON:ERGO Ergomed (ERGO) Share Price, News & Analysis → SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad) Free ERGO Stock Alerts GBX 1,346 0.00 (0.00%) (As of 11/13/2023) Add Compare Share Share Today's Range 1,346▼ 1,34650-Day Range 1,346▼ 1,34652-Week Range 895▼ 1,380Volume280,999 shsAverage Volume346,578 shsMarket Capitalization£701.00 millionP/E Ratio4,641.38Dividend YieldN/APrice TargetGBX 1,400 Stock AnalysisStock AnalysisAnalyst ForecastsChartHeadlinesInsider TradesStock AnalysisAnalyst ForecastsChartHeadlinesInsider Trades Get Ergomed alerts: Email Address Ad Stansberry ResearchThe "Smart Money" Is Ready for May 1st Are You?Former Wall Street VP: "Buy This Stock Now" Five of America's Most Successful Investors Bought Shares in The Same Company. One Former Wall St. Trader Explains Why… About Ergomed Stock (LON:ERGO)Ergomed plc, together with its subsidiaries, provides clinical trial planning, management, and monitoring; and drug safety and medical information services in the United Kingdom, rest of Europe, the Middle East, Africa, North America, and internationally. The company operates through two segments, Clinical Research Services and Pharmacovigilance. It provides and manages clinical development, trial management, and pharmacovigilance services for pharmaceutical, biotechnology, and generics companies. The company focuses on various therapeutic areas, including oncology, hematology, allergy, respiratory, and neurology/CNS, as well as develops orphan drugs. It also provides site support services. The company was formerly known as Ergomed Clinical Research Limited and changed its name to Ergomed plc in June 2014. Ergomed plc was founded in 1997 and is headquartered in Guildford, the United Kingdom.Read More ERGO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ERGO Stock News HeadlinesFebruary 6, 2024 | morningstar.comIcon PLC IJFJanuary 14, 2024 | finanznachrichten.deGreen Mining Innovation: Neuer Chief Financing OfficerApril 24, 2024 | Stansberry Research (Ad)The "Smart Money" Is Ready for May 1st Are You?Former Wall Street VP: "Buy This Stock Now" Five of America's Most Successful Investors Bought Shares in The Same Company. January 13, 2024 | finanznachrichten.deGreen Mining Innovation: New Chief Financing OfficerJanuary 4, 2024 | msn.comPermira Hires Maschmeyer From Vistria for Health-Care InvestingDecember 31, 2023 | msn.com3 high-growth penny stocks to consider buying for 2024November 14, 2023 | finance.yahoo.comErgomed strongly positioned for future growth in new partnership with PermiraOctober 19, 2023 | uk.finance.yahoo.comInvesco Ltd: Form 8.3 - Ergomed PLCApril 24, 2024 | Stansberry Research (Ad)The "Smart Money" Is Ready for May 1st Are You?Former Wall Street VP: "Buy This Stock Now" Five of America's Most Successful Investors Bought Shares in The Same Company. October 10, 2023 | msn.comWakefield-based fds advises on sale of an Isle of Man pharmaceutical company to global firm Ergomed PLCOctober 2, 2023 | uk.finance.yahoo.comMan Group PLC : Form 8.3 - Ergomed plcSeptember 22, 2023 | marketwatch.comErgomed Expects to Meet Full-Year Views After Pretax Profit Edged UpSeptember 18, 2023 | finance.yahoo.comForm 8.3 - Ergomed_PLCSeptember 12, 2023 | finanznachrichten.deSamson Rock Capital LLP - Form 8.3 - Ergomed PlcSeptember 7, 2023 | finance.yahoo.comForm 8.3 - ERGO LNSeptember 5, 2023 | msn.comPrivate equity swoops on UK pharma firm in £703.1m deal: Ergomed founder lands £120m windfallSeptember 5, 2023 | msn.comLife science founder net worth tops £120m after private equity swoopSeptember 4, 2023 | msn.comPrivate equity swoops on UK pharma firm Ergomed in £703.1m dealSeptember 4, 2023 | thetimes.co.ukUK’s Ergomed agrees £703m takeover by private equity firm PermiraSeptember 4, 2023 | markets.businessinsider.comErgomed Share Price Surges Over 14% on Takeover AnnouncementSeptember 4, 2023 | ft.comErgomed/Permira: buyout group sees drug trial group as contract thrillerSeptember 4, 2023 | uk.finance.yahoo.comForm 8.3 - Octopus Investments - Ergomed plcSeptember 4, 2023 | msn.comBidco to acquire biopharmaceutical services company ErgomedSeptember 4, 2023 | msn.comSignal: UK clinical trials provider Ergomed bought out in $888m dealSeptember 4, 2023 | yahoo.comFTSE 100 Live: Asia shares lift, blue-chips seen higherSeptember 4, 2023 | msn.comPrivate equity firm Permira to buy UK's Ergomed for 703 million poundsSeptember 4, 2023 | reuters.comUK's Ergomed agrees for 703 million pound buyout deal with PermiraSee More Headlines Receive ERGO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ergomed and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings9/18/2017Today4/24/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolLON:ERGO CUSIPN/A CIKN/A Webwww.ergomedplc.com Phone+44-1483-503205FaxN/AEmployees1,400Year FoundedN/APrice Target and Rating Average Stock Price TargetGBX 1,400 High Stock Price TargetGBX 1,450 Low Stock Price TargetGBX 1,350 Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)GBX 0.29 Trailing P/E Ratio4,641.38 Forward P/E RatioN/A P/E GrowthN/ANet Income£15 million Net Margins9.87% Pretax MarginN/A Return on Equity18.08% Return on Assets10.16% Debt Debt-to-Equity Ratio3.32 Current Ratio1.79 Quick Ratio1.22 Sales & Book Value Annual Sales£152.09 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow54.67 Book ValueGBX 179 per share Price / BookN/AMiscellaneous Outstanding Shares52,080,000Free FloatN/AMarket Cap£701.00 million OptionableNot Optionable Beta0.79 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesDr. Miroslav Reljanovic (Age 64)Founder & Executive Chairman Comp: $964.3kMr. Michael William Spiteri (Age 62)Chief Transformation & Technology Officer Comp: $52.77kJonathan Andrew Curtain (Age 47)CFO & Executive Director Dr. Michael ForstnerHead of Risk Management & PharmacoepidemiologyMs. Sally AmanuelPresident of PrimeVigilanceDr. Gordana TonkovicPresident of Clinical ResearchMs. Ronel SteynSenior Vice President of Global DevelopmentKeith ByrneSenior Vice-President of Capital Markets & StrategyJoanne BletcherCompany SecretaryMore ExecutivesKey CompetitorsPureTech HealthLON:PRTCOxford Nanopore TechnologiesLON:ONTSilence TherapeuticsLON:SLNHorizon Discovery Group plc (HZD.L)LON:HZDGenusLON:GNSView All Competitors ERGO Stock Analysis - Frequently Asked Questions Should I buy or sell Ergomed stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ergomed in the last twelve months. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" ERGO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ERGO, but not buy additional shares or sell existing shares. View ERGO analyst ratings or view top-rated stocks. What is Ergomed's stock price target for 2024? 3 equities research analysts have issued twelve-month price targets for Ergomed's stock. Their ERGO share price targets range from GBX 1,350 to GBX 1,450. On average, they predict the company's stock price to reach GBX 1,400 in the next twelve months. This suggests a possible upside of 4.0% from the stock's current price. View analysts price targets for ERGO or view top-rated stocks among Wall Street analysts. How have ERGO shares performed in 2024? Ergomed's stock was trading at GBX 1,346 at the beginning of the year. Since then, ERGO stock has increased by 0.0% and is now trading at GBX 1,346. View the best growth stocks for 2024 here. How were Ergomed's earnings last quarter? Ergomed plc (LON:ERGO) announced its quarterly earnings data on Monday, September, 18th. The company reported $1.20 earnings per share for the quarter. The firm earned $22.91 million during the quarter. Ergomed had a net margin of 9.87% and a trailing twelve-month return on equity of 18.08%. What other stocks do shareholders of Ergomed own? Based on aggregate information from My MarketBeat watchlists, some companies that other Ergomed investors own include Dicerna Pharmaceuticals (DRNA), AbbVie (ABBV), Axsome Therapeutics (AXSM), FuelCell Energy (FCEL), NIO (NIO), Science Applications International (SAIC), Northern Dynasty Minerals (NAK), Tilray (TLRY), Agilent Technologies (A) and American Express (AXP). How do I buy shares of Ergomed? Shares of ERGO stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. This page (LON:ERGO) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarThe A.I. story nobody is telling you (Read ASAP)TradeSmithtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencySHOCKING Crypto Leak…Crypto 101 MediaDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsThe #1 Crypto for 2024InvestorPlaceDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ergomed plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.